Avalo Therapeutics (AVTX) 10-Q2020 Q1 Quarterly report

Filed: 7 May 20, 4:04pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: accrual, acute, Aevi, Aid, ALI, alleviate, antibody, AOSD, attorney, autoimmune, Barer, biomarker, Bruhn, buyout, Christopher, Cola, complaint, covenant, Crohn, CSO, cytokine, de, digit, disregarded, divestiture, doubt, draft, duration, enclosed, endoscopy, epidemic, franchise, Garry, Genie, Genomic, geography, globe, Glycoprotein, Grano, hospitalized, HSV, HVEM, impute, infected, Jane, Jeffrey, Joseph, Jr, Kathleen, LeoGroup, lifted, lung, Lymphatic, mediation, Medicine, Mike, Miller, monetized, monoclonal, month, moratorium, mTOR, Myeloma, Neil, notably, onset, OSI, outbreak, Overview, pandemic, paused, Pennsylvania, proclamation, rata, reconcile, remotely, renamed, Reorganization, repay, respiratory, resume, salary, shift, Sol, spread, Steve, Sullivan, Suzanne, tentatively, Teva, transform, Trump, Trust, trustee, Watson, Wayne, Wuhan

Removed: absence, adjust, adjustment, aggressively, arbitration, Arbor, attestation, attributable, baseline, bearing, blood, book, borrowing, canceled, candidate, caption, carryforward, challenge, charge, classification, clinically, collectible, comparative, competitive, component, concomitant, consecutive, consolidating, consulting, contemplated, contingency, contingently, counterclaimant, counterparty, court, data, deductible, deducting, deemed, defendant, deficiency, denied, description, determinable, dictated, dietary, differentiate, disaggregated, discounted, distributor, diverse, diversified, document, dollar, eligibility, eliminate, enable, escalating, estimating, exclude, exclusive, exclusively, exclusivity, exemption, existed, existence, expedient, expenditure, favorable, finalized, finance, flowing, footprint, forecast, forward, greater, growing, guideline, handling, headquarter, healthy, hearing, hypotension, identifying, impacting, impairment, inception, incremental, indemnify, indemnity, indirect, informational, informed, integration, intellectual, interpreted, introduction, involving, issuable, joint, lack, legal, leveraging, lice, marketability, marketed, Master, meaningful, modify, negotiation, Neurogenic, nOH, nonclinical, notice, obligated, obtained, orthostatic, outdated, ownership, package, packaged, PAI, panel, Parkinson, passed, patent, pattern, penalty, performed, periodic, placebo, PLC, policy, population, positive, practical, practice, preliminary, pressure, prevent, proceed, professional, program, promote, provision, purpose, rapid, reach, readily, reassessed, reclassed, redundant, reimbursable, reimbursement, relation, representation, representative, request, requiring, resold, robust, safe, safety, satisfied, SBP, seller, selling, Shionogi, short, Simplification, single, Sklice, Steven, stipulated, substrate, successful, sustained, systolic, tangible, test, tested, therapy, tolerability, type, unamortized, underwriting, unrelated, updated, USA, user, varying, waiver, written

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

AVTX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Cerecor Inc. (the “Registrant”) on Form 10-Q for the period ended March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael Cola, Chief Executive Officer of the Registrant, and I, Christopher Sullivan, Interim Chief Financial Officer of the Registrant, each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:


1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and


2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.



Date: May 7, 2020			/s/ Michael Cola
			Michael Cola
			Chief Executive Officer
			(Registrant’s principal executive officer)



Date: May 7, 2020			/s/ Christopher Sullivan
			Christopher Sullivan
			Interim Chief Financial Officer
			(Registrant’s principal financial officer and principal accounting officer)

The foregoing certifications are not deemed filed with the Securities and Exchange Commission for purposes of section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of Cerecor Inc. under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.